Asset
Quisovalimab
Avalo Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05288504 | phase2 | completed | 2022-02-24 | 2023-05-11 | Avalo Therapeutics, Inc. | A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma. |
| NCT03169894 | phase1 | terminated | 2017-07-14 | 2021-09-14 | Avalo Therapeutics, Inc. | Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis |
FDA applications (0)
This company has no applications containing this asset.